Armored RNA Quant ™ Development of Armored RNA ® as a Primary Standard June 5, 2003 Cindy WalkerPeach, Ph.D. Director of Research and cGMP Operations Ambion.

Slides:



Advertisements
Similar presentations
Dr. Thaweesak Tirawatnapong Chula Medical Research Center (Chula MRC)
Advertisements

Alternative Calibration Strategies for the Clinical Laboratory: Application to Nortriptyline Therapeutic Drug Monitoring M.T. Olson, A. Breaud, R. Harlan,
REAL TIME PCR ………A step forward in medicine
Yi-Chen Yang, Drug Biology Division Bureau of Food and Drug Analysis Department of Health, Taiwan Collaborative study for establishment of the first national.
Karen Cristiano Biologicals Unit, CRIVIB Calibration against the WHO Standards of National Reference Preparations for detection of blood viruses by NAT:
Linearity Panels HIV RNA, HCV RNA, HBV DNA, and CMV DNA
World Health Organization
Copyright © 2007 Asuragen, Inc NAT Testing in Solid Tissues and Organs: A Pre-analytical Solution for Nucleic Acid Stabilization Cindy WalkerPeach, Ph.D.
Summary 1 l The Analytical Problem l Data Handling.
Enzyme-linked Immunosorbent Assay
CBER's policies on assay regulation: Definitions of assay performance characteristics Andrew I. Dayton, M.D., Ph.D. CBER.
Plant virus infections induce tremendous economic losses for agricultural production each year in the U.S. Accurate and reliable diagnosis of the pathogens.
QC/QA Mary Malarkey Director, Division of Case Management Office of Compliance and Biologics Quality Center for Biologics Evaluation and Research March.
Requirements for Premarket Submissions: In vitro Diagnostic Instrumentation and Software Related to Donor Screening and HIV Diagnostic Assay Systems Diane.
CBER Blood Establishment Registration and Product Listing Jan O’Brien Blood Registration Coordinator DBA, OBRR, CBER September 15, 2009.
The Human Transcription Factor Proteome Andrew Stergachis Stamatoyannopoulos Lab Dept. of Genome Sciences University of Washington.
JENN SHAFNER BRIAN KROUSE CLINT KEHRES. Pre ISO 9000  The BS 5750 standard required factories to document manufacturing procedures.  BS 5750 was known.
Page 1  2011 all rights reserved - no copy and distribution without permission! Microlife Corporation
Generic Automated Sample Preparation for Commercial NAT Assays
Regulatory Overview.
HIV, HCV, and HBV NAT Controls Formulation, Stability and Performance Mark Manak BBI Diagnostics, Inc. A Division of SeraCare Life Sciences, Inc. SoGAT.
NIST Standard Reference Material Project: Pure DNA Standard for Cytomegalovirus SoGAT XX Warsaw, Poland June 13,2007 Marcia Holden.
Ensuring Product Quality in Gene Transfer Clinical Trials
Industrial equipment manufacturing Special and large machinery Special and large machinery Oil, gas, and mining machinery Oil, gas, and mining machinery.
CE MARKING OF IVDDs - the NIBSC perspective Morag Ferguson Division of Virology.
3rd Dimension of Product Translation: Industrialization
CCR5 Monoclonal Antibody PRO 140 Inhibited HIV-1 Resistant to Maraviroc, a Small Molecule CCR5 Antagonist Andre J Marozsan Progenics Pharmaceuticals, Inc.
1 Global Biomarker Standardization Consortium: CSF Reference Method Sub-group Chairs: Kaj Blennow & Henrik Zetterberg.
Qualification Panels for West Nile Virus RNA Tests Mark Manak, Ph.D. Boston Biomedica, Inc. West Bridgewater, MA SoGAT Langen, Germany July 3, 2003.
1 PAT and Biological Products Tom Layloff FDA-SGE Management Sciences for Health The views expressed here are those of the author and not necessarily.
Stability of HCV, HIV-1 and HBV nucleic acids in plasma samples stored at different temperatures Marta José, Rodrigo Gajardo and Juan I. Jorquera Instituto.
Yi-Chen Yang, Yu-Hsuan Chen, Show-Lan Chiu, Hwei-Fang Cheng Drug Biology Division, Bureau of Food and Drug Analysis Department of Health, Taiwan, ROC National.
Quality Control Lecture 5
SynTura: A New Ribonuclease Resistant Viral RNA Control Material Ralf Schönbrunner, Ph.D. SoGAT XXI Brussels, Belgium May 28, 2009.
The Use of Pooled Viral Load Testing to Identify Antiretroviral Treatment Failure Davey Smith 1, Susanne May 2, Josué Perez-Santiago 1, Matthew Strain.
Development of Standard Reagents for WNV NAT M. Rios, A. Grinev, K. Sirnivasan, O. Wood, S. Daniel, I. Hewlett CBER/FDA.
History of ILC Involvement in NAT Standardization 1998: Inter-Organization Discussion for the Establishment of Standard Reference Material for Nucleic.
Overview of FDA's Regulatory Framework for PET Drugs
Controls for Blood Septicemia Nucleic Acid Tests Mark Manak BBI Diagnostics, Inc. A Division of SeraCare Life Sciences, Inc. SoGAT XIX Meeting Berne, Switzerland.
Standardization of NAT Extraction Methods Paul D. Neuwald, PhD AcroMetrix Corporation, Benicia, CA SoGAT XVIII Bethesda, MD, USA May 24, 2005.
Presentation on Longhorn Vaccine & Diagnostics LLC PrimeStore® Suite of Products and Pipeline 1747 Citadel Plaza, Suite 206, San Antonio, Texas
Challenges of Bridging Studies in Biomarker Driven Clinical Trials May 19, MBSW Conference. Muncie, IN. Szu-Yu Tang, Chang Xu, Bonnie LaFleur May.
Consent Decree Update Cecily Kodis Kaufman CBER/OCBQ/DCM September 20, 2001.
Who makes up all these rules?? A discussion on Regulatory Agencies and how they relate to each other and our lab.
International Scientific Workshop on the Standardization of Genome Amplification Techniques for the Safety Testing of Blood, Tissues and Organs With Regard.
SMARTAR: small RNA transcriptome analyzer Geuvadis RNA analysis meeting April 16 th 2012 Esther Lizano and Marc Friedländer Xavier Estivill lab Programme.
QC/QA.
Sampling and Analysis of Isocyanates Used in Paints Robert P. Streicher National Institute for Occupational Safety and Health Publications of the U.S.
DISCONTINUATION OR NO DISCONTIUNATION: COMPARISON OF SINGLE UNIT HIV ANTIGEN TESTING VS. POOLED NAT TESTING Gerald Schochetman, Ph.D. Abbott Laboratories.
Development and Characterization of Synthetic Standards: HCV RNA Susan E. Bromley, Ph.D. Director, Product Development Bayer Healthcare Diagnostics 24.
Estimating measurement uncertainty
Confidential Extending the Armored RNA Technology to DNA Cindy WalkerPeach, Ph.D. Director, Development and Operations Ambion Diagnostics BSI EN ISO9001:2000.
LECTURE 13 QUALITY ASSURANCE METHOD VALIDATION
Progress on Study to Validate Synthetic Materials for Use as Calibrators and References SoGAT XIX Bern, 14 June 2006 Roberta M. Madej Roche Molecular Diagnostics.
Alpha Measurement and Control from a Supplier Perspective Presented by Jerry Cohn, President PURE TECHNOLOGIES.
Telephone: Global In-Vitro Diagnostics (IVD) Market Report: 2015 Edition.
HBV viral load 측정 및 임상적 의의 진단검사의학과이희주 Content v 임상적 의의 v 측정법.
Still a Hard-to-Reach Population? Using Social Media to Recruit Latino Gay Couples for an HIV/STI Prevention Intervention Adaptation Study Omar Martinez,
Robert S. Wright US EPA, Research Triangle Park, NC EPA Protocol Gases Fall 2012 Update PurityPlus Specialty Gas Producers.
Results and Discussion
Harvey Holmes, Clare Morris and Neil Berry Division of Retrovirology
Comparison of Methods used for DNA Quantification
Roche Molecular Diagnostics
Volume 10, Issue 4, Pages (April 1999)
Feasibility of Synthetic Materials as Primary Standards
For Campus-wide Business Managers Meeting June 16, 2016
Medical Device Design and Development
Tyrosinase-Based Reporter Gene for Photoacoustic Imaging of MicroRNA-9 Regulated by DNA Methylation in Living Subjects  Haifeng Zheng, Lin Zhou, Yaru.
Volume 27, Issue 11, Pages e3 (June 2017)
Immuno-MS results from antibodies toward 20 different target proteins in HeLa cell lysates. Immuno-MS results from antibodies toward 20 different target.
Presentation transcript:

Armored RNA Quant ™ Development of Armored RNA ® as a Primary Standard June 5, 2003 Cindy WalkerPeach, Ph.D. Director of Research and cGMP Operations Ambion Diagnostics, Austin, Texas USA BSI EN ISO9001:2000 Certified Quality System Regulations (21CFR§820) BSI Registration Number: FM Medical Device Manufacturing Owner/Operator Number: SoGAT 2003

Armored RNA Quant  RNA Controls and Standards Stable – ribonuclease resistant Homogenous – single, sequence-defined transcript Quantifiable – known copy number Compatible – performs broadly with RNA-base viral assay technologies Flexible – allows for addition to human matrix of choice Non-infectious – ease in handling and shipping

Armored RNA Quant  In vivo Armored RNA Packaging System

Armored RNA Quant  RNA Controls and Standards Stable – ribonuclease resistant Homogenous – single, sequence-defined transcript Directly Quantifiable – known copy number Compatible – performs broadly with RNA-base viral assay technologies Flexible – allows for addition to human matrix of choice Non-infectious – ease in handling and shipping

Armored RNA Quant  In vitro Armored RNA Packaging System

Armored RNA Quant  In vitro Armored RNA Quantification Phosphate Assay Set up standard curve (concentration vs. OD 600 ), using a phosphate standard from NIST Digest Armored RNA by phosphodiesterase and alkaline phosphatase to nucleosides and inorganic phosphate Measure the phosphate concentration of the digested Armored RNA and calculate the value using the standard curve

Armored RNA Quant  In vitro Armored RNA Quantification Phosphate Assay Inorganic phosphate standard curve used to determine copy number (4.6 copies) of HIV RNA in each Armored RNA particle

Armored RNA Quant  In vitro Armored RNA Quantification HPLC Assay Set up standard curve (concentration vs. peak area) for standard ribonucleosides (A, U, C, G) by HPLC Digest Armored RNA, using phosphodiesterase and alkaline phosphate to nucleosides and inorganic phosphate Measure the nucleoside peak areas by HPLC Based on the Armored RNA sequence, calculate the concentration of the RNA in the Armored RNA preparation

Armored RNA Quant  In vitro Armored RNA Quantification HPLC Assay Determination of RNA concentration by HPLC

Armored RNA Quant  In vitro Armored RNA Quantification HPLC Assay HPLC assay standard curves used to determine copy number (4.1 copies) of HIV RNA in each Armored RNA particle

Armored RNA Quant  In vitro Armored RNA Quantification Comparison Phosphate Assay HPLC Assay Roche Monitor ® Assay Batch Batch Determination of RNA copy number per Armored RNA particle Roche Amplicor Monitor Assay results consistent with those of NIST-traceable phosphate assay and standardized HPLC assay in the quantification of in vitro Armored RNA, within a 20% error range

Armored RNA Quant  Summary An in vitro Armored RNA ® packaging system has been developed to produce Armored RNA that is comprised entirely of a single, defined transcript (target sequence), allowing for direct quantification by two independent, direct, physical methods (NIST- traceable phosphate assay and standardized HPLC assay) Acknowledgements Jun Wang Ginny Lai Marty Badgett Britt Pasloske The project described was supported by grant number AI40529 from the NIH. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH awarding component. Armored RNA ® technology was jointly developed by Ambion, Inc. and Cenetron Diagnostics, LLC. Armored RNA ® is a registered trademark of Ambion and Cenetron.